SynthesisFrontiers in pharmacology2025
Cluster of differentiation 38 monoclonal antibody therapy in the treatment of multiple myeloma: a systematic review and meta-analysis.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Linking CD38 Cell Surface Expression to the Unique Calcium Flux Properties in Human Peripheral B Lymphocytes Following anti-IgM and anti-IgG Stimulation.Journal of immunology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cluster of differentiation 38 (CD38) monoclonal antibodies, including daratumumab and isatuximab, have demonstrated clinical activity in relapsed or refractory multiple myeloma (MM). This study aims to systematically evaluate the efficacy and safety of CD38-targeted monoclonal antibodies compared with those of standard regimens. Methods: This study searched PubMed, the Cochrane Library, Web of Science, and Embase from inception until 30 June 2025 for randomized controlled trials (RCTs) comparing CD38 antibodies (alone or in combination) with proteasome inhibitor- or immunomodulatory agent-based control regimens in adults with multiple myeloma. Two reviewers independently screened the studies, extracted data, and assessed the risk of bias (Cochrane risk of bias 2.0). Pooled risk ratios (RRs) and hazard ratios (HRs) were estimated using fixed- or random-effects models according to I Results: A total of eight RCTs with 2,821 patients were included. The pooled overall response rate (ORR) was significantly improved with CD38-targeted therapies (RR 1.59; 95% confidence interval [CI] 1.32-1.92; Conclusion: CD38 monoclonal antibodies enhance the depth of response and prolong progression-free survival in multiple myeloma, with an acceptable safety profile, supporting their integration into treatment algorithms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.